Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
2d
PsyPost on MSNOzempic blindness? Serious vision problems reported in patients taking weight loss medicationsA new study published JAMA Ophthalmology has brought attention to a series of vision problems observed in patients taking ...
A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
The School of Medicine is a major international centre for teaching and research, and committed to the pursuit of improved human health. We combine progressive healthcare education and patient care ...
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Deputies are advising everyone to talk to their primary care provider if they suffer from a similar condition and to make sure they have Glucagon Nasal Powder spray (BAQSIMI) so that medical ...
Get Instant Summarized Text (Gist) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked to an increased risk of thyroid cancer in the first year of treatment for type 2 diabetes ...
Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results